

Giorgio Arnaldi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5365074/publications.pdf>

Version: 2024-02-01

143
papers

8,815
citations

50244

46
h-index

45285

90
g-index

150
all docs

150
docs citations

150
times ranked

6096
citing authors

#	ARTICLE	IF	CITATIONS
1	Diagnosis and Complications of Cushing's Syndrome: A Consensus Statement. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 5593-5602.	1.8	1,184
2	A Survey on Adrenal Incidentaloma in Italy. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 637-644.	1.8	723
3	A Survey on Adrenal Incidentaloma in Italy. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 637-644.	1.8	693
4	AME Position Statement on adrenal incidentaloma. European Journal of Endocrinology, 2011, 164, 851-870.	1.9	435
5	Clinically Guided Genetic Screening in a Large Cohort of Italian Patients with Pheochromocytomas and/or Functional or Nonfunctional Paragangliomas. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 1541-1547.	1.8	284
6	High cardiovascular risk in patients with Cushing's syndrome according to 1999 WHO/ISH guidelines. Clinical Endocrinology, 2004, 61, 768-777.	1.2	239
7	Approach to the Patient with Possible Cushing's Syndrome. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 3121-3131.	1.8	219
8	Adrenal Incidentaloma: An Overview of Hormonal Data from the National Italian Study Group. Hormone Research, 1997, 47, 284-289.	1.8	159
9	AMP-activated protein kinase mediates glucocorticoid-induced metabolic changes: a novel mechanism in Cushing's syndrome. FASEB Journal, 2008, 22, 1672-1683.	0.2	148
10	Pathophysiology of Dyslipidemia in Cushing's Syndrome. Neuroendocrinology, 2010, 92, 86-90.	1.2	147
11	Germline NF1 Mutational Spectra and Loss-of-Heterozygosity Analyses in Patients with Pheochromocytoma and Neurofibromatosis Type 1. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 2784-2792.	1.8	126
12	Efficacy and safety of once-monthly pasireotide in Cushing's disease: a 12 month clinical trial. Lancet Diabetes and Endocrinology, 2018, 6, 17-26.	5.5	116
13	Conventional and Nuclear Medicine Imaging in Ectopic Cushing's Syndrome: A Systematic Review. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 3231-3244.	1.8	113
14	Body Composition and Metabolic Features in Women with Adrenal Incidentaloma or Cushing's Syndrome. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 5301-5306.	1.8	109
15	Expression Profiles for Steroidogenic Enzymes in Adrenocortical Disease. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 5446-5455.	1.8	104
16	COVID-19 infection and glucocorticoids: update from the Italian Society of Endocrinology Expert Opinion on steroid replacement in adrenal insufficiency. Journal of Endocrinological Investigation, 2020, 43, 1141-1147.	1.8	103
17	Adrenal incidentaloma. Best Practice and Research in Clinical Endocrinology and Metabolism, 2012, 26, 405-419.	2.2	94
18	Cardiovascular Risk In Cushing's Syndrome. Pituitary, 2004, 7, 253-256.	1.6	93

#	ARTICLE	IF	CITATIONS
19	Novel Somatic Mutations in the Catalytic Subunit of the Protein Kinase A as a Cause of Adrenal Cushing's Syndrome: A European Multicentric Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, E2093-E2100.	1.8	92
20	Italian Addison Network Study: Update of Diagnostic Criteria for the Etiological Classification of Primary Adrenal Insufficiency. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 1598-1604.	1.8	83
21	Body Composition and Metabolic Features in Women with Adrenal Incidentaloma or Cushing's Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 5301-5306.	1.8	83
22	Changes in Adenosine 5â€²-Monophosphate-Activated Protein Kinase as a Mechanism of Visceral Obesity in Cushingâ€™s Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008, 93, 4969-4973.	1.8	76
23	MANAGEMENT APPROACHES TO ADRENAL INCIDENTALOMAS. <i>Endocrinology and Metabolism Clinics of North America</i> , 2000, 29, 107-125.	1.2	71
24	Use of the Desmopressin Test in the Differential Diagnosis of Pseudo-Cushing State from Cushingâ€™s Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 1115-1122.	1.8	70
25	Advances in the epidemiology, pathogenesis, and management of Cushingâ€™s syndrome complications. <i>Journal of Endocrinological Investigation</i> , 2012, 35, 434-448.	1.8	69
26	Prognostic factors in ectopic Cushingâ€™s syndrome due to neuroendocrine tumors: a multicenter study. <i>European Journal of Endocrinology</i> , 2017, 176, 453-461.	1.9	66
27	Hypertension-induced changes of platelet-derived growth factor receptor expression in rat aorta and heart. <i>Hypertension</i> , 1991, 17, 888-895.	1.3	65
28	Cyclical Cushingâ€™s Syndrome in a Patient with a Bronchial Neuroendocrine Tumor (Typical Carcinoid) Expressing Ghrelin and Growth Hormone Secretagogue Receptors. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003, 88, 5834-5840.	1.8	64
29	Natural history of gastro-entero-pancreatic and thoracic neuroendocrine tumors. Data from a large prospective and retrospective Italian epidemiological study: the NET management study. <i>Journal of Endocrinological Investigation</i> , 2012, 35, 817-23.	1.8	64
30	Effect of a six-month treatment with lanreotide on cardiovascular risk factors and arterial intima-media thickness in patients with acromegaly. <i>European Journal of Endocrinology</i> , 2002, 146, 303-309.	1.9	63
31	A multicenter experience on the prevalence of ARMC5 mutations in patients with primary bilateral macronodular adrenal hyperplasia: from genetic characterization to clinical phenotype. <i>Endocrine</i> , 2017, 55, 959-968.	1.1	62
32	Harmful effects of functional hypercortisolism: a working hypothesis. <i>Endocrine</i> , 2014, 46, 370-386.	1.1	60
33	Variable Expression of the V1 Vasopressin Receptor Modulates the Phenotypic Response of Steroid-Secreting Adrenocortical Tumors. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1998, 83, 2029-2035.	1.8	59
34	Variable Expression of the V1 Vasopressin Receptor Modulates the Phenotypic Response of Steroid-Secreting Adrenocortical Tumors1. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1998, 83, 2029-2035.	1.8	58
35	Coenzyme Q10 levels in idiopathic and varicocele-associated asthenozoospermia. <i>Andrologia</i> , 2002, 34, 107-111.	1.0	58
36	Laparoscopic adrenalectomy: a report on 50 operations. <i>European Journal of Endocrinology</i> , 1998, 138, 548-553.	1.9	57

#	ARTICLE	IF	CITATIONS
37	Bone mineral density in acromegaly: the effect of gender, disease activity and gonadal status. <i>Clinical Endocrinology</i> , 2003, 58, 725-731.	1.2	55
38	Bone metabolism and mass in women with Cushing's syndrome and adrenal incidentaloma. <i>Clinical Endocrinology</i> , 2002, 57, 587-593.	1.2	53
39	Prevalence of AIP mutations in a large series of sporadic Italian acromegalic patients and evaluation of CDKN1B status in acromegalic patients with multiple endocrine neoplasia. <i>European Journal of Endocrinology</i> , 2010, 163, 369-376.	1.9	53
40	Pegvisomant in acromegaly: an update. <i>Journal of Endocrinological Investigation</i> , 2017, 40, 577-589.	1.8	53
41	Self image and quality of life in acromegaly. <i>Pituitary</i> , 2002, 5, 17-19.	1.6	52
42	Coagulopathy in Cushing's Syndrome. <i>Neuroendocrinology</i> , 2010, 92, 55-59.	1.2	52
43	Second-line tests in the differential diagnosis of ACTH-dependent Cushing's syndrome. <i>Pituitary</i> , 2016, 19, 488-495.	1.6	52
44	High-Dose and High-Frequency Lanreotide Autogel in Acromegaly: A Randomized, Multicenter Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 2454-2464.	1.8	51
45	Targeting Estrogen Receptor- α Reduces Adrenocortical Cancer (ACC) Cell Growth in Vitro and in Vivo: Potential Therapeutic Role of Selective Estrogen Receptor Modulators (SERMs) for ACC Treatment. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, E2238-E2250.	1.8	50
46	Treatment-related fatigue with sorafenib, sunitinib and pazopanib in patients with advanced solid tumors: An up-to-date review and meta-analysis of clinical trials. <i>International Journal of Cancer</i> , 2015, 136, 1-10.	2.3	47
47	Expression of the Novel Adrenocorticotropin-Responsive Gene Selective Alzheimer's Disease Indicator-1 in the Normal Adrenal Cortex and in Adrenocortical Adenomas and Carcinomas. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 1332-1339.	1.8	46
48	Association of glucocorticoid receptor polymorphism A3669G with decreased risk of developing diabetes in patients with Cushing's syndrome. <i>European Journal of Endocrinology</i> , 2012, 166, 35-42.	1.9	46
49	Bone complications in patients with Cushing's syndrome: looking for clinical, biochemical, and genetic determinants. <i>Osteoporosis International</i> , 2014, 25, 913-921.	1.3	44
50	First-line therapy of acromegaly: A statement of the A.L.I.C.E. (Acromegaly primary medical treatment) Tj ETQq0 0 0 rgBT /Overlock 10 Tt <i>Endocrinological Investigation</i> , 2006, 29, 1017-1020.	1.8	43
51	Efficacy of the new long-acting formulation of lanreotide (Lanreotide Autogel) in somatostatin analogue-naïve patients with acromegaly. <i>Journal of Endocrinological Investigation</i> , 2009, 32, 202-209.	1.8	43
52	Effects of hypertension and aging on platelet-derived growth factor and platelet-derived growth factor receptor expression in rat aorta and heart.. <i>Hypertension</i> , 1991, 18, III93-9.	1.3	43
53	Apparent mineralocorticoid excess type II. <i>Steroids</i> , 1994, 59, 80-83.	0.8	42
54	Adrenal incidentaloma. <i>Brazilian Journal of Medical and Biological Research</i> , 2000, 33, 1177-1189.	0.7	42

#	ARTICLE	IF	CITATIONS
55	Growth Hormone Receptor Variants and Response to Pegvisomant in Monotherapy or in Combination with Somatostatin Analogs in Acromegalic Patients: A Multicenter Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, E165-E172.	1.8	41
56	Long-term treatment of Cushing's disease with pasireotide: 5-year results from an open-label extension study of a Phase III trial. <i>Endocrine</i> , 2017, 57, 156-165.	1.1	40
57	Human corticotropin releasing hormone test performance in the differential diagnosis between Cushing's disease and pseudo-Cushing state is enhanced by combined ACTH and cortisol analysis. <i>European Journal of Endocrinology</i> , 2009, 160, 891-898.	1.9	38
58	Reduced expression of the growth hormone and type 1 insulin-like growth factor receptors in human somatotroph tumours and an analysis of possible mutations of the growth hormone receptor. <i>Clinical Endocrinology</i> , 2003, 59, 328-338.	1.2	37
59	Corticotrophin-releasing hormone and desmopressin tests in the differential diagnosis between Cushing's disease and pseudo-Cushing state: a comparative study. <i>Clinical Endocrinology</i> , 2011, 75, 666-672.	1.2	37
60	Glucocorticoid excess and COVID-19 disease. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2021, 22, 703-714.	2.6	36
61	Pegvisomant in acromegaly: Why, when, how. <i>Journal of Endocrinological Investigation</i> , 2007, 30, 693-699.	1.8	35
62	Cytotoxic T lymphocyte antigen-4 Ala17 polymorphism is a genetic marker of autoimmune adrenal insufficiency: Italian association study and meta-analysis of European studies. <i>European Journal of Endocrinology</i> , 2010, 162, 361-369.	1.9	35
63	A venous thromboembolism risk assessment model for patients with Cushing's syndrome. <i>Endocrine</i> , 2016, 52, 322-332.	1.1	35
64	Acth receptor mRNA in human adrenocortical tumors: Overexpression in aldosteronomas. <i>Endocrine Research</i> , 1998, 24, 845-849.	0.6	34
65	Isolation and characterization of progenitor mesenchymal cells in human pituitary tumors. <i>Cancer Gene Therapy</i> , 2015, 22, 9-16.	2.2	34
66	Acromegaly Is More Severe in Patients With <i>AHR</i> or <i>AIP</i> Gene Variants Living in Highly Polluted Areas. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 1872-1879.	1.8	34
67	Towards the tailoring of glucocorticoid replacement in adrenal insufficiency: the Italian Society of Endocrinology Expert Opinion. <i>Journal of Endocrinological Investigation</i> , 2020, 43, 683-696.	1.8	34
68	The medical treatment with pasireotide in Cushing's disease: an Italian multicentre experience based on "real-world evidence". <i>Endocrine</i> , 2019, 64, 657-672.	1.1	33
69	Adrenocorticotropin and Cortisol Hyperresponsiveness to Hexarelin in Patients with Cushing's Disease Bearing a Pituitary Microadenoma, But Not in Those with Macroadenoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1998, 83, 4207-4211.	1.8	32
70	Hypertension due to renal artery occlusion in a patient with antiphospholipid syndrome. <i>American Journal of Hypertension</i> , 2001, 14, 62-65.	1.0	32
71	Different expression of protein kinase A (PKA) regulatory subunits in cortisol-secreting adrenocortical tumors: Relationship with cell proliferation. <i>Experimental Cell Research</i> , 2008, 314, 123-130.	1.2	32
72	The degree of urinary hypercortisolism is not correlated with the severity of Cushing's syndrome. <i>Endocrine</i> , 2017, 55, 564-572.	1.1	32

#	ARTICLE	IF	CITATIONS
73	Telomerase Activity Is Significantly Enhanced in Malignant Adrenocortical Tumors in Comparison to Benign Adrenocortical Adenomas. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2000, 85, 468-470.	1.8	31
74	Mitotane Concentrations Influence the Risk of Recurrence in Adrenocortical Carcinoma Patients on Adjuvant Treatment. <i>Journal of Clinical Medicine</i> , 2019, 8, 1850.	1.0	31
75	Analysis of GPR101 and AIP genes mutations in acromegaly: a multicentric study. <i>Endocrine</i> , 2016, 54, 762-767.	1.1	30
76	Adrenal incidentaloma: Surgical update. <i>Journal of Endocrinological Investigation</i> , 2007, 30, 200-204.	1.8	28
77	Sexual Dysfunctions in Men Affected by Autoimmune Addison's Disease Before and After Short-Term Gluco- and Mineralocorticoid Replacement Therapy. <i>Journal of Sexual Medicine</i> , 2013, 10, 2036-2043.	0.3	28
78	Approach to hyponatremia according to the clinical setting: Consensus statement from the Italian Society of Endocrinology (SIE), Italian Society of Nephrology (SIN), and Italian Association of Medical Oncology (AIOM). <i>Journal of Endocrinological Investigation</i> , 2018, 41, 3-19.	1.8	28
79	The diagnostic accuracy of increased late night salivary cortisol for Cushing's syndrome: a real-life prospective study. <i>Journal of Endocrinological Investigation</i> , 2019, 42, 327-335.	1.8	28
80	Mitotane Concentrations Influence Outcome in Patients with Advanced Adrenocortical Carcinoma. <i>Cancers</i> , 2020, 12, 740.	1.7	28
81	Investigation protocol: adrenal enlargement. <i>Clinical Endocrinology</i> , 1999, 50, 141-146.	1.2	27
82	A Single-Center 10-Year Experience with Pasireotide in Cushing's Disease: Patients' Characteristics and Outcome. <i>Hormone and Metabolic Research</i> , 2016, 48, 290-298.	0.7	26
83	Up-to 5-year efficacy of pasireotide in a patient with Cushing's disease and pre-existing diabetes: literature review and clinical practice considerations. <i>Pituitary</i> , 2015, 18, 359-365.	1.6	25
84	Primary adrenal hypercortisolism: minimally invasive surgical treatment or medical therapy? A retrospective study with long-term follow-up evaluation. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2010, 24, 2542-2546.	1.3	24
85	<scp>ACROSCORE</scp>: a new and simple tool for the diagnosis of acromegaly, a rare and underdiagnosed disease. <i>Clinical Endocrinology</i> , 2016, 84, 380-385.	1.2	24
86	RNA Sequencing and Somatic Mutation Status of Adrenocortical Tumors: Novel Pathogenetic Insights. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e4459-e4473.	1.8	24
87	Variable Expression of the Transcription Factors cAMP Response Element-Binding Protein and Inducible cAMP Early Repressor in the Normal Adrenal Cortex and in Adrenocortical Adenomas and Carcinomas. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 5443-5449.	1.8	22
88	Hypercoagulability in patients with Cushing disease detected by thrombin generation assay is associated with increased levels of neutrophil extracellular trap-related factors. <i>Endocrine</i> , 2017, 56, 298-307.	1.1	22
89	Adrenocorticotropin and Cortisol Hyperresponsiveness to Hexarelin in Patients with Cushing's Disease Bearing a Pituitary Microadenoma, But Not in Those with Macroadenoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1998, 83, 4207-4211.	1.8	22
90	A novel endothelial tyrosine kinase cDNA homologous to platelet-derived growth factor receptor cDNA. <i>Biochemical and Biophysical Research Communications</i> , 1992, 186, 706-714.	1.0	21

#	ARTICLE	IF	CITATIONS
91	Increased frequency of the rs2066853 variant of aryl hydrocarbon receptor gene in patients with acromegaly. <i>Clinical Endocrinology</i> , 2014, 81, 249-253.	1.2	21
92	Transforming growth factor- β 1 is more expressed in thyroid follicular adenoma than in normal tissue. <i>Journal of Endocrinological Investigation</i> , 1994, 17, 335-340.	1.8	20
93	Enhanced expression of transforming growth factor β 21 in rat thyroid hyperplasia is thyrotropin induced and time dependent. <i>European Journal of Endocrinology</i> , 1996, 134, 373-378.	1.9	20
94	Effects of long-term treatment with human pure follicle-stimulating hormone on semen parameters and sperm-cell ultrastructure in idiopathic oligoteratoasthenozoospermia. <i>Andrologia</i> , 2000, 32, 155-161.	1.0	20
95	Salivary cortisol is a useful tool to assess the early response to pasireotide in patients with Cushing's disease. <i>Pituitary</i> , 2015, 18, 60-67.	1.6	20
96	Impact of COVID-19 pandemic on psychophysical stress in patients with adrenal insufficiency: the CORTI-COVID study. <i>Journal of Endocrinological Investigation</i> , 2021, 44, 1075-1084.	1.8	20
97	Laurdan ⁺ —Laurdan, Molecular Probes, Eugene, Oregon. fluorescence: a simple method to evaluate sperm plasma membrane alterations. <i>Fertility and Sterility</i> , 2001, 76, 501-505.	0.5	19
98	Diagnostic accuracy of increased urinary cortisol/cortisone ratio to differentiate ACTH-dependent Cushing's syndrome. <i>Clinical Endocrinology</i> , 2017, 87, 500-507.	1.2	19
99	Adrenal morpho-functional alterations in patients with acromegaly. <i>Journal of Endocrinological Investigation</i> , 2008, 31, 602-606.	1.8	18
100	Pasireotide for the treatment of Cushing's disease. <i>Expert Opinion on Investigational Drugs</i> , 2010, 19, 889-898.	1.9	18
101	How to improve effectiveness of pegvisomant treatment in acromegalic patients. <i>Journal of Endocrinological Investigation</i> , 2018, 41, 575-581.	1.8	18
102	Pituitary adenomas, stem cells, and cancer stem cells: what's new?. <i>Journal of Endocrinological Investigation</i> , 2018, 41, 745-753.	1.8	17
103	Decreased expression of insulin-sensitive glucose transporter mRNA (GLUT-4) in adipose tissue of non-insulin-dependent diabetic and obese patients: Evaluation by a simplified quantitative PCR assay. <i>Journal of Endocrinological Investigation</i> , 1994, 17, 709-715.	1.8	16
104	Severe hypomagnesaemia-induced hypocalcaemia in a patient with Gitelman's syndrome. <i>Clinical Endocrinology</i> , 2002, 56, 413-418.	1.2	16
105	Vasopressin receptors modulate the pharmacological phenotypes of cushing's syndrome. <i>Endocrine Research</i> , 1998, 24, 807-816.	0.6	15
106	Levoketoconazole in the Treatment of Patients With Cushing's Syndrome and Diabetes Mellitus: Results From the SONICS Phase 3 Study. <i>Frontiers in Endocrinology</i> , 2021, 12, 595894.	1.5	15
107	Functional and Nonfunctional Adrenocortical Tumors Demonstrate a High Responsiveness to Low-Dose Adrenocorticotropin. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003, 88, 1994-1998.	1.8	14
108	Androgens in Cushing's Syndrome. <i>Frontiers of Hormone Research</i> , 2019, 53, 77-91.	1.0	14

#	ARTICLE	IF	CITATIONS
109	Expression of growth hormone-releasing hormone receptor splicing variants in human primary adrenocortical tumours. <i>Clinical Endocrinology</i> , 2005, 62, 533-538.	1.2	13
110	The role of an acute pasireotide suppression test in predicting response to treatment in patients with Cushing's disease: findings from a pilot study. <i>Endocrine</i> , 2015, 50, 154-161.	1.1	12
111	Hypothalamic-Pituitary Diseases and Erectile Dysfunction. <i>Journal of Clinical Medicine</i> , 2021, 10, 2551.	1.0	12
112	Effects of somatostatin and its analogues on progenitor mesenchymal cells isolated from human pituitary adenomas. <i>Pituitary</i> , 2017, 20, 251-260.	1.6	11
113	ENSAT registry-based randomized clinical trials for adrenocortical carcinoma. <i>European Journal of Endocrinology</i> , 2021, 184, R51-R59.	1.9	11
114	Telomerase Activity Is Significantly Enhanced in Malignant Adrenocortical Tumors in Comparison to Benign Adrenocortical Adenomas. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2000, 85, 468-470.	1.8	11
115	Fine-needle aspiration cytology of adrenal masses: a re-assessment with histological confirmation. <i>Journal of Endocrinological Investigation</i> , 2012, 35, 590-4.	1.8	11
116	Intrapituitary cytokines in Cushing's disease: do they play a role?. <i>Pituitary</i> , 2011, 14, 236-241.	1.6	10
117	Ultrasound-based detection of glucocorticoid-induced impairments of muscle mass and structure in Cushing's disease. <i>Journal of Endocrinological Investigation</i> , 2019, 42, 757-768.	1.8	10
118	Acromegaly and male sexual health. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2022, 23, 671-678.	2.6	10
119	Sodium alterations impair the prognosis of hospitalized patients with COVID-19 pneumonia. <i>Endocrine Connections</i> , 2021, 10, 1344-1351.	0.8	8
120	New treatment guidelines on Cushing's disease. <i>F1000 Medicine Reports</i> , 2009, 1, .	2.9	7
121	Fracture risk assessment before and after resolution of endogenous hypercortisolism: Is the FRAX® algorithm useful?. <i>Journal of Endocrinological Investigation</i> , 2014, 37, 957-965.	1.8	7
122	Is pasireotide-induced diabetes mellitus predictable? A pilot study on the effect of a single dose of pasireotide on glucose homeostasis. <i>Pituitary</i> , 2020, 23, 534-542.	1.6	7
123	MTHFR C677T polymorphism, folate status and colon cancer risk in acromegalic patients. <i>Pituitary</i> , 2014, 17, 257-66.	1.6	6
124	Angiotensin II Receptors in Cortical and Medullary Adrenal Tumors. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1997, 82, 865-869.	1.8	6
125	Transforming Growth Factor β 1: Implications in Adrenocortical Tumorigenesis. <i>Endocrine Research</i> , 2000, 26, 905-910.	0.6	5
126	Long-term safety and efficacy of Omnitrope® in adults with growth hormone deficiency: Italian interim analysis of the PATRO Adults study. <i>Journal of Endocrinological Investigation</i> , 2017, 40, 669-678.	1.8	5

#	ARTICLE	IF	CITATIONS
127	Copeptin and Stress. <i>Endocrines</i> , 2021, 2, 384-404.	0.4	5
128	Unusual clinical manifestation of pheochromocytoma in a MEN2A patient. <i>Journal of Endocrinological Investigation</i> , 2002, 25, 53-57.	1.8	4
129	Advances in medical treatment of Cushing's disease. <i>Expert Review of Endocrinology and Metabolism</i> , 2007, 2, 735-743.	1.2	4
130	Somatic PRKACA Mutations: Association With Transition From Pituitary-Dependent to Adrenal-Dependent Cushing Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 5651-5657.	1.8	4
131	Cushing Syndrome: The Role of MSCs in Wound Healing, Immunosuppression, Comorbidities, and Antioxidant Imbalance. <i>Frontiers in Cell and Developmental Biology</i> , 2019, 7, 227.	1.8	4
132	Personality (at Intrapsychic and Interpersonal Level) Associated With Quality of Life in Patients With Cancer (Lung and Colon). <i>Cancer Control</i> , 2019, 26, 107327481988056.	0.7	4
133	Safety and effectiveness of Omnitrope® in patients with growth hormone deficiency: snapshot analysis of PATRO Adults study in the Italian population. <i>Journal of Endocrinological Investigation</i> , 2021, 44, 327-337.	1.8	4
134	COVID-19 and endocrine and metabolic disorders: critical points and suggestions for a correct therapeutic management from a tertiary endocrine center in Italy. <i>Minerva Endocrinology</i> , 2022, 47, .	0.6	4
135	Mesenchymal Stem Cells Exposed to Persistently High Glucocorticoid Levels Develop Insulin-Resistance and Altered Lipolysis: A Promising In Vitro Model to Study Cushing's Syndrome. <i>Frontiers in Endocrinology</i> , 2022, 13, 816229.	1.5	4
136	Update on Hypercortisolism Therapy. <i>Frontiers of Hormone Research</i> , 2016, 46, 87-105.	1.0	3
137	Mutational analysis of StAR gene in adrenal tumors. <i>International Journal of Cancer</i> , 2002, 97, 357-360.	2.3	2
138	Osilodrostat oral tablets for adults with Cushing's disease. <i>Expert Review of Endocrinology and Metabolism</i> , 2022, , 1-11.	1.2	2
139	Pituitary-directed medical treatment of Cushing's disease. <i>Expert Review of Endocrinology and Metabolism</i> , 2009, 4, 263-272.	1.2	1
140	Masse surrenaliche incidentali: protocollo diagnostico. <i>L Endocrinologo</i> , 2000, 1, 55-62.	0.0	0
141	Somatic Mutation Analysis of the MEN1 Gene in Adrenocortical Tumors Using Denaturing Gradient Gel Electrophoresis (DGGE). <i>International Journal on Disability and Human Development</i> , 2001, 2, .	0.2	0
142	Diagnosi della sindrome di Cushing. <i>L Endocrinologo</i> , 2005, 6, 137-142.	0.0	0
143	Histological Contamination in Clinical Research"from Ultrastructure to Stem Cell Biology. , 2020, , 57-69.		0